Is tofacitinib monotherapy also effective for the treatment of Acrodermatitis continua of Hallopeau?
- 21 November 2024
- journal article
- letter
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , e283-e285
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (82074246, 82374272.)
This publication has 5 references indexed in Scilit:
- Spesolimab Response in a Girl With Acrodermatitis Continua of HallopeauJAMA Dermatology, 2024
- A retrospective analysis of 65 patients with acrodermatitis continua of HallopeauExperimental Dermatology, 2024
- Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other dayJournal of Dermatological Treatment, 2024
- Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinibEuropean Journal Of Dermatology, 2023
- Inhibition of Progression of Acrodermatitis Continua of Hallopeau With BaricitinibJAMA Dermatology, 2021